INCB123667

DRUG4 trials

Sponsors

Incyte Corporation

Conditions

Healthy ParticipantsOvarian Cancer

Phase 1

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

RecruitingNCT06909162

Incyte CorporationHealthy Participants

Start: 2025-05-05End: 2026-05-17Target: 51Updated: 2026-03-23

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

CompletedNCT07218744

Incyte CorporationHealthy Participants

Start: 2025-11-13End: 2025-12-10Updated: 2026-01-07

Phase 2

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07023627

Incyte CorporationOvarian Cancer

Start: 2025-11-12End: 2027-10-24Target: 160Updated: 2026-03-16

Phase 3

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

RecruitingNCT07214779

Incyte CorporationOvarian Cancer

Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-03-23